Objective Capital Management LLC Invests $667,000 in Edwards Lifesciences Co. (NYSE:EW)

Objective Capital Management LLC acquired a new position in Edwards Lifesciences Co. (NYSE:EW - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 10,110 shares of the medical research company's stock, valued at approximately $667,000.

A number of other institutional investors and hedge funds have also made changes to their positions in EW. Empowered Funds LLC increased its stake in Edwards Lifesciences by 151.2% during the 1st quarter. Empowered Funds LLC now owns 20,123 shares of the medical research company's stock valued at $1,923,000 after purchasing an additional 12,112 shares in the last quarter. SG Americas Securities LLC lifted its position in Edwards Lifesciences by 236.4% in the 1st quarter. SG Americas Securities LLC now owns 97,554 shares of the medical research company's stock valued at $9,322,000 after acquiring an additional 68,556 shares in the last quarter. Oppenheimer & Co. Inc. boosted its stake in Edwards Lifesciences by 23.4% during the 1st quarter. Oppenheimer & Co. Inc. now owns 26,253 shares of the medical research company's stock valued at $2,509,000 after purchasing an additional 4,977 shares during the last quarter. Illinois Municipal Retirement Fund increased its holdings in shares of Edwards Lifesciences by 116.3% in the 1st quarter. Illinois Municipal Retirement Fund now owns 92,023 shares of the medical research company's stock worth $8,794,000 after purchasing an additional 49,484 shares in the last quarter. Finally, Forsta AP Fonden raised its stake in shares of Edwards Lifesciences by 9.4% in the first quarter. Forsta AP Fonden now owns 146,100 shares of the medical research company's stock worth $13,961,000 after purchasing an additional 12,600 shares during the last quarter. Institutional investors own 79.46% of the company's stock.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Daveen Chopra sold 1,250 shares of Edwards Lifesciences stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total value of $87,437.50. Following the completion of the transaction, the vice president now directly owns 29,333 shares of the company's stock, valued at $2,051,843.35. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. In other news, VP Daveen Chopra sold 1,250 shares of the firm's stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total value of $87,437.50. Following the completion of the sale, the vice president now directly owns 29,333 shares of the company's stock, valued at $2,051,843.35. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Larry L. Wood sold 25,000 shares of the business's stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the transaction, the insider now directly owns 198,526 shares in the company, valued at approximately $13,084,848.66. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 41,250 shares of company stock worth $2,746,988. Insiders own 1.29% of the company's stock.

Edwards Lifesciences Price Performance

Shares of EW traded up $0.39 during midday trading on Friday, hitting $66.23. 3,088,441 shares of the company traded hands, compared to its average volume of 5,173,085. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.87 and a current ratio of 3.71. The firm has a 50 day moving average of $67.59 and a 200-day moving average of $76.96. The stock has a market cap of $39.06 billion, a price-to-earnings ratio of 9.56, a PEG ratio of 3.70 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, meeting the consensus estimate of $0.67. The business had revenue of $1.35 billion during the quarter, compared to analysts' expectations of $1.57 billion. Edwards Lifesciences had a return on equity of 22.56% and a net margin of 70.82%. The firm's revenue for the quarter was up 8.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.59 EPS. On average, analysts forecast that Edwards Lifesciences Co. will post 2.57 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Royal Bank of Canada dropped their price objective on Edwards Lifesciences from $85.00 to $75.00 and set an "outperform" rating on the stock in a research report on Tuesday, October 8th. Sanford C. Bernstein raised shares of Edwards Lifesciences from a "strong sell" rating to a "hold" rating in a report on Monday, October 28th. Wells Fargo & Company dropped their target price on shares of Edwards Lifesciences from $90.00 to $80.00 and set an "overweight" rating on the stock in a report on Monday, September 9th. Morgan Stanley reiterated an "equal weight" rating and set a $70.00 target price on shares of Edwards Lifesciences in a research note on Friday, October 11th. Finally, Daiwa America cut Edwards Lifesciences from a "strong-buy" rating to a "hold" rating in a report on Wednesday, October 30th. Seventeen research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat, Edwards Lifesciences currently has an average rating of "Hold" and a consensus price target of $75.67.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.